| Autor: |
Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD, Griffiths, Robert I, Lalla, Deepa, Herbert, Robert J, Doan, Justin F, Brammer, Melissa G, Danese, Mark D |
| Zdroj: |
Cancer Investigation; Nov2011, Vol. 29 Issue 9, p573-584, 12p |
| Abstrakt: |
We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR] 0.54; 95% Confidence Interval [CI] 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
